Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Nicolas Sommer"'
Autor:
Stephanie J. Yaung, Christine Ju, Sandeep Gattam, Alan Nicholas, Nicolas Sommer, Johanna C. Bendell, Herbert I. Hurwitz, John J. Lee, Fergal Casey, Richard Price, John F. Palma
Publikováno v:
Cancers, Vol 14, Iss 9, p 2240 (2022)
Sequencing circulating tumor DNA (ctDNA) from liquid biopsies may better assess tumor heterogeneity than limited sampling of tumor tissue. Here, we explore ctDNA-based heterogeneity and its correlation with treatment outcome in STEAM, which assessed
Externí odkaz:
https://doaj.org/article/09876e3ee7c94bc282334283ad7da6d9
Autor:
Scott Kopetz, Funda Meric-Bernstam, Richard Lanman, Nicolas Sommer, Gabi Tarcic, Johnique Atkins, Helen Huang, Imad Shureiqi, Jorge Bellido, David Fogelman, Apostolia M. Tsimberidou, Bryan Kee, Vivek Subbiah, Sarina Piha-Paul, Michael J. Overman, Siqing Fu, Filip Janku, Alexey V. Sorokin, Badi El Osta, Van K. Morris, David S. Hong
68-gene panel for which mutation, amplification, deletion, and fusion profiling was available.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3681f852407b8186787cfdf5049965d
https://doi.org/10.1158/2159-8290.22531259.v1
https://doi.org/10.1158/2159-8290.22531259.v1
Autor:
Scott Kopetz, Funda Meric-Bernstam, Richard Lanman, Nicolas Sommer, Gabi Tarcic, Johnique Atkins, Helen Huang, Imad Shureiqi, Jorge Bellido, David Fogelman, Apostolia M. Tsimberidou, Bryan Kee, Vivek Subbiah, Sarina Piha-Paul, Michael J. Overman, Siqing Fu, Filip Janku, Alexey V. Sorokin, Badi El Osta, Van K. Morris, David S. Hong
Trends in various mutation allele frequencies tracked serially over treatment course for two patients on study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b25b81379f1f04219a9303526fc87e5
https://doi.org/10.1158/2159-8290.22531271
https://doi.org/10.1158/2159-8290.22531271
Autor:
Scott Kopetz, Funda Meric-Bernstam, Richard Lanman, Nicolas Sommer, Gabi Tarcic, Johnique Atkins, Helen Huang, Imad Shureiqi, Jorge Bellido, David Fogelman, Apostolia M. Tsimberidou, Bryan Kee, Vivek Subbiah, Sarina Piha-Paul, Michael J. Overman, Siqing Fu, Filip Janku, Alexey V. Sorokin, Badi El Osta, Van K. Morris, David S. Hong
Demographic information for patients on study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14ab9f3a80a8bec3d620097307c303e1
https://doi.org/10.1158/2159-8290.22531256
https://doi.org/10.1158/2159-8290.22531256
Autor:
Scott Kopetz, Funda Meric-Bernstam, Richard Lanman, Nicolas Sommer, Gabi Tarcic, Johnique Atkins, Helen Huang, Imad Shureiqi, Jorge Bellido, David Fogelman, Apostolia M. Tsimberidou, Bryan Kee, Vivek Subbiah, Sarina Piha-Paul, Michael J. Overman, Siqing Fu, Filip Janku, Alexey V. Sorokin, Badi El Osta, Van K. Morris, David S. Hong
Trends in cfDNA fraction (black) and radiographic changes (red) for ten other patients on study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22d994b66e25b6506e8fbe2dc7dda5cc
https://doi.org/10.1158/2159-8290.22531268
https://doi.org/10.1158/2159-8290.22531268
Autor:
Scott Kopetz, Funda Meric-Bernstam, Richard Lanman, Nicolas Sommer, Gabi Tarcic, Johnique Atkins, Helen Huang, Imad Shureiqi, Jorge Bellido, David Fogelman, Apostolia M. Tsimberidou, Bryan Kee, Vivek Subbiah, Sarina Piha-Paul, Michael J. Overman, Siqing Fu, Filip Janku, Alexey V. Sorokin, Badi El Osta, Van K. Morris, David S. Hong
Analysis of BRAFV600E allele fraction by cfDNA was validated using two separate methodologies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56c6c75a187f9fb44d291cc756052362
https://doi.org/10.1158/2159-8290.22531265
https://doi.org/10.1158/2159-8290.22531265
Autor:
John F. Palma, Stephanie J. Yaung, Lijing Yao, Nalin Tikoo, Nicolas Sommer, Richard Price, Alan Nicholas, Christoph Mancao, Alex Lovejoy, John J. Lee, Christine Ju, Herbert I. Hurwitz, Johanna C. Bendell, Xiaoju Max Ma
Supplementary Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f0820ef485cebc980515f1becfcc42a
https://doi.org/10.1158/1078-0432.22473869.v1
https://doi.org/10.1158/1078-0432.22473869.v1
Autor:
John F. Palma, Stephanie J. Yaung, Lijing Yao, Nalin Tikoo, Nicolas Sommer, Richard Price, Alan Nicholas, Christoph Mancao, Alex Lovejoy, John J. Lee, Christine Ju, Herbert I. Hurwitz, Johanna C. Bendell, Xiaoju Max Ma
Supplementary Table 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a662070de9feeb8a935cbe2326fe821
https://doi.org/10.1158/1078-0432.22473857.v1
https://doi.org/10.1158/1078-0432.22473857.v1
Autor:
John F. Palma, Stephanie J. Yaung, Lijing Yao, Nalin Tikoo, Nicolas Sommer, Richard Price, Alan Nicholas, Christoph Mancao, Alex Lovejoy, John J. Lee, Christine Ju, Herbert I. Hurwitz, Johanna C. Bendell, Xiaoju Max Ma
Purpose:We assessed plasma circulating tumor DNA (ctDNA) level as a prognostic marker for progression-free survival (PFS) following first-line metastatic colorectal cancer (mCRC) therapy.Experimental Design:The Sequencing Triplet With Avastin and Mai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84b3b0b36a87507864e7e4b8cb2ea3f8
https://doi.org/10.1158/1078-0432.c.6528626.v1
https://doi.org/10.1158/1078-0432.c.6528626.v1
Autor:
Daneng Li, Nicolas Sommer, Wendy Verret, Riad Salem, Riccardo Lencioni, Sairy Hernandez, Beiying Ding
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5437-5447 (2021)
Cancer Medicine
Cancer Medicine
Background IMbrave150 is a phase III trial that assessed atezolizumab + bevacizumab (ATEZO/BEV) versus sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (HCC) and demonstrated a significant improvement in clinical outcomes. Explo